Cadenza Bio, Inc. was founded in 2022 to accelerate and support the development of a series of novel, non-steroidal, highly selective compounds targeting Estrogen Receptor β (ERβ). Our patented and patent-pending compounds have shown therapeutic efficacy in preclinical animal models of Multiple Sclerosis and Endometriosis.
Our goal goes beyond incremental improvements. We are dedicated to breaking the cycle of disease and, in doing so, transforming lives. We aim not only to alleviate symptoms but to halt progression, promote repair, and restore quality of life to enable total activity, empowering patients to regain control over their health.
Company Details
- Employees
- 5
- Founded
- -
- Address
- This Condition And Deliver Lasting Relief. Through Collaboration
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.cadenza.bio/
Cadenza Bio Questions
Cadenza Bio's website is https://www.cadenza.bio/
Cadenza Bio's LinkedIn profile is https://www.linkedin.com/company/cadenza-bio
Cadenza Bio has
5 employees.
View email and phone details for 5
employees at Cadenza Bio.
Cadenza Bio's industry is
Biotechnology Research
Cadenza Bio's categories are Biotechnology Research
Cadenza Bio's founding year is 2022
